Perspectives
Integrated analysis confirms decision to remove Entresto® from UM
April 1, 2020Unique cost of care study on sacubitril-valsartan (sac-val) shows significant medical cost savings for adherent users; also, advanced analytics adds insights to impact UM for all users
Heart failure is the leading cause of death in the U.S. Sac-val is proven to decrease hospitalization and reduce death due to heart failure with reduced ejection fraction (HFrEF), also known as systolic heart failure.
As a knowledge management company, Prime wanted to study real world integrated benefits data on use of sac-val for adherent members, as well as all sac-val utilizing members.
This study looked at more than 1,000 members newly initiating sac-val. For an adherent members taking sac-val, after just one year:
- Medical costs decreased 38%
- Hospital costs decreased 69%
- Emergency room costs decreased 44%
- Total cost of care decreased 22%
When looking at the entire cohort (including adherent and nonadherent members), the cohort still showed a small total decrease in cost of care (2%). Prime’s recommendation to its health plan clients is to offer sac-val on an open formulary. Eliminating the prior authorization fast-tracks member access. This can save lives and health care costs.
Related news
Perspectives
April 17, 2024
AMCP 2024: Behind the research with YuQian Liu
Ahead of her session with Andy Killpack, Liu — senior director of specialty clinical solutions at Prime/MRx — shares current care management strategies for cell and gene therapy and the future of this exciting frontier
Perspectives
April 16, 2024
AMCP 2024: Behind the research with Jacob LaRue and Timothy O’Shea
Ahead of their session, Jacob and Timothy share how Prime/MRx is working alongside providers like Horizon Blue Cross Blue Shield of New Jersey to manage drug waste and rein in spend for specialty drugs without therapeutic impact to patients
Perspectives
April 15, 2024
Oncology Insights: Cancer treatment is personal
Precision medicine, or personalized medicine, uses genes or proteins to diagnose or treat disease. This medical care design has significantly impacted oncology and grew out of a need to improve and individualize patient treatments